Free Trial
→ Read this warning immediately (From Porter & Company) (Ad)tc pixel
NASDAQ:COGT

Cogent Biosciences Q1 2025 Earnings Report

Cogent Biosciences logo
$32.72 -2.09 (-6.01%)
Closing price 03:59 PM Eastern
Extended Trading
$32.97 +0.25 (+0.77%)
As of 05:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Cogent Biosciences EPS Results

Actual EPS
-$0.52
Consensus EPS
-$0.56
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Cogent Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cogent Biosciences Announcement Details

Quarter
Q1 2025
Date
5/6/2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 6, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Cogent Biosciences' Q2 2026 earnings is estimated for Tuesday, August 4, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, August 5, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Cogent Biosciences' Q1 2025 Press ReleasePress Release
(8-K)
Cogent Biosciences' Q1 2025 Quarterly reportQuarterly report
(10-Q)

Cogent Biosciences Earnings Headlines

Cogent Biosciences Reports PEAK Phase 3 Trial Results Demonstrating Significant PFS Improvement with Bezuclastinib Combination in GIST Patients
May 30 at 8:30 AM  |  quiverquant.comQ
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
May 30 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/30/3303872/0/en/cogent-biosciences-announces-detailed-clinical-data-from-peak-phase-3-trial-with-bezuclastinib-in-combination-with-sunitinib-in-gastrointestinal-stromal-tumors-gist-at-2026-america.html
Stranded On The Flood Plains of History
The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar.tc pixel
June 2 at 1:00 AM  |  Porter & Company (Ad)
Cogent Biosciences (NASDAQ:COGT) Receives "Outperform" Rating from Wedbush
May 30 at 3:37 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30809033
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Consensus Rating of "Moderate Buy" from Analysts
May 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30806550
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST
May 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/28/3302753/0/en/cogent-biosciences-announces-fda-acceptance-of-new-drug-application-nda-with-priority-review-for-bezuclastinib-in-combination-with-sunitinib-for-patients-with-gist.html
See More Cogent Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cogent Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cogent Biosciences and other key companies, straight to your email.

About Cogent Biosciences

Cogent Biosciences (NASDAQ:COGT) is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors. Preclinical studies have demonstrated the candidate’s ability to deplete immunosuppressive macrophages within the tumor microenvironment, resulting in antitumor activity as a monotherapy and in combination with checkpoint inhibitors. Cogent continues to explore additional novel small molecules that can influence immune-regulatory pathways in oncology.

Founded in 2016 and headquartered in Cambridge, Massachusetts, Cogent Biosciences completed its initial public offering in 2020 and maintains operations in key U.S. research hubs. The company leverages collaborative partnerships with academic institutions and contract research organizations to advance its pipeline efficiently. While most of its clinical programs are currently being evaluated in North America, Cogent is positioned to pursue international trial sites as it progresses through later-stage development.

Under the leadership of President and Chief Executive Officer Daniel Welch, Cogent Biosciences is guided by a management team with deep experience in oncology drug development, translational research, and regulatory strategy. The company’s board and scientific advisory committees include experts in immuno-oncology and precision medicine, supporting its mission to bring novel targeted therapies to patients with unmet medical needs.

View Cogent Biosciences Profile
Earnings Tools